Daily antibiotic use came out on top when compared with several other strategies for managing recurrent urinary tract infections (UTIs), but daily cranberry pills, daily estrogen therapy, and acupuncture also had good showings of cost-effectiveness.
A new ambulatory noninvasive ventilation device is proving effective at increasing exercise tolerance for patients with COPD, an important factor for improving patient outcomes and quality of life.
For many COPD patients, a simple walk from one room to the next can be exhausting. For respiratory therapists and pulmonary physicians, improving the exercise tolerance of COPD patients is key to improving their lives, since a chief complaint is often their inability to participate in everyday activities.
Clarus Therapeutics, Inc., today announced the submission of a New
Drug Application (NDA) for Rextoro™ (formerly CLR-610), the
Company’s oral testosterone (T) replacement product, to the
U.S. Food and Drug Administration (FDA). Efficacy consistent
with the current FDA mandate for T-replacement products was
achieved in two Phase 3 studies. After protocol-prescribed
dose titration, at least 75% of men treated with Rextoro achieved
average serum T levels (C‑avg) in the normal range (between 300 –
1,000 ng/dL).
By Sabriya Rice
The specter of superbugs spreading through U.S. hospitals has public health experts debating what hospitals should do to deal with such outbreaks. An incident last year in Park Ridge, Ill., may point the way to one approach that could help, according to a report by the Centers for Disease Control and Prevention.
Investigator(s):
The Lundquist Institute
Some 2.5 million people around the world have multiple sclerosis (MS), a potentially debilitating disease in which the body’s immune system destroys the protective sheath (myelin) that covers nerves.
This damage interferes with the communication between the brain, spinal cord and other parts of the body, causing symptoms that can range from a mild weakness to an inability to walk or speak clearly. There is no cure for MS, but there are some preliminary data showing that Vitamin D, retinoic acid or Vitamin A, may help alleviate these symptoms.
Brad Spellberg is a professor of medicine at the Los Angeles Biomedical Research Institute at Harbor-U.C.L.A. Medical Center. He is the co-author of “Rising Plague: The Deadly Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them.”
Investigator(s):
The Lundquist Institute
The ASCO Post
By Caroline Helwick
December 15, 2013, Volume 4, Issue 20
According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the 2013 European Cancer Congress byRowan T. Chlebowski, MD, PhD, Professor and Chief of Medical Oncology/Hematology at the David Geffen School of Medicine at UCLA and Harbor-UCLA Medical Center, Los Angeles.1
Important Findings
Investigator(s):
The Lundquist Institute
LOS ANGELES – (Dec. 5, 2013) – In a finding that could expand the use of one of the most effective forms of birth control, two intrauterine contraceptive systems that had lower doses of the contraceptive hormone, levonorgestrel, were found to be safe and effective in preventing pregnancies, according to an international study that included researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).
Investigator(s):
The Lundquist Institute
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) will honor one of the Palos Verdes Estate’s leading businessmen and philanthropists, Ralph Scriba, with its Award for Community Service, and one of its most distinguished researchers, Kouichi R. “Corky” Tanaka, MD, of Rancho Palos Verdes, with its Award for Inspirational Leadership at the institute’s Translating Science and Transforming Lives Gala Dec. 5 at the Beverly Wilshire Hotel in Beverly Hills.